Related references
Note: Only part of the references are listed.Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
Hojjat Ahmadzadehfar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Robert Seifert et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)
The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu-PSMA therapy
Anna Yordanova et al.
PROSTATE (2020)
Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
Robert Seifert et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
Justin Ferdinandus et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study
Andrei Gafita et al.
EUROPEAN UROLOGY (2020)
Improving quality of life in patients with metastatic prostate cancer following one cycle of(177)Lu-PSMA-617 radioligand therapy: a pilot study
Milka Marinova et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2020)
Clinical Outcomes of 177Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy
Thomas W. Barber et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Is the Vision of Radioligand Therapy for Prostate Cancer Becoming a Reality? An Overview of the Phase III VISION Trial and Its Importance for the Future of Theranostics
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)
Michael S. Hofman et al.
BJU INTERNATIONAL (2019)
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
Anna Yordanova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer
Matthias M. Heck et al.
EUROPEAN UROLOGY (2019)
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617
Katharina Kessel et al.
THERANOSTICS (2019)
Delayed response after repeated Lu-177-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
Kambiz Rahbar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
K. Rahbar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience
Kalevi Kairemo et al.
CURRENT RADIOPHARMACEUTICALS (2018)
The impact of repeated cycles of radioligand therapy using [177Lu] Lu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer
Anna Yordanova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer
Axel Braeuer et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
Hojjat Ahmadzadehfar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride
Hojjat Ahmadzadehfar et al.
ONCOTARGET (2017)
Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Clemens Kratochwil et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
Harshad R. Kulkarni et al.
JOURNAL OF NUCLEAR MEDICINE (2016)
The Prognostic Importance of Metastatic Site in Men with Metastatic Castration-resistant Prostate Cancer
Gregory R. Pond et al.
EUROPEAN UROLOGY (2014)
An updated Declaration of Helsinki will provide more protection
Cecil B. Wilson
NATURE MEDICINE (2013)
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
C. Parker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Share Paper
